Sub-Licensees

 

Aurobindo

Sub-licences covering: daclatasvir (DCV), lopinavir/ritonavir (LPV/r), tenofovir alafenamide (TAF), atazanavir (ATV), abacavir (ABC), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

Aurobindo, Bristol-Myers Squibb and the MPP signed a sub-licensing agreement in April 2016 allowing Aurobindo to develop daclatasvir (DCV).

In December 2015, following the announcement of MPP’s agreement with AbbVie, Aurobindo signed a sub-licensing agreement to produce lopinavir and ritonavir (LPV/r) for Africa.

In September 2014, Aurobindo, the MPP and Gilead Sciences signed a sub-licensing agreement, which replaces the previous one signed in September 2011, allowing Aurobindo to manufacture the novel investigational medicines tenofovir alafenamide (TAF), as well as  emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG]. The agreement was amended and restated in April 2016.

In July 2014, the MPP, Aurobindo and Bristol-Myers Squibb signed a new sublicencing agreement allowing it to manufacture atazanavir (ATV).

In June 2013, the MPP signed a sublicensing agreement with Aurobindo allowing it to manufacture abacavir (ABC) for paediatric use. This sublicensing agreement has been amended in November 2014 following the announcement of the extension of the MPP-ViiV Healthcare licence agreement to 121 countries.

 

top

Cipla

Sub-licences covering: daclatasvir (DCV), atazanavir (ATV), tenefovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], dolutegravir (DTG)

In December 2015,  Bristol-Myers Squibb, the MPP and Cipla signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In November 2014, Cipla, the MPP and Bristol-Myers Squibb signed a sublicensing agreement related to the antiretroviral medicines atazanavir (ATV).

In September 2014, Cipla, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Cipla to manufacture the novel investigational medicines tenofovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG]. The agreement was amended and restated in October 2015.

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Cipla allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

 

Desano

Sub-licences covering: lopinavir/ritonavir(LPV/r), dolutegravir (DTG), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI) and atazanavir (ATV)

The MPP, Desano and AbbVie signed a sub-licensing agreement, in June 2016, covering lopinavir/ritonavir (LPV/r) for Africa.

In November 2014, the MPP, Desano and ViiV Healthcare signed a sub-licensing agreement allowing Desano to manufacture dolutegravir (DTG) for adults and paediatrics use. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

In August 2015, the MPP, Desano and Gilead Sciences signed a sub-licensing agreement, which replaces the previous one signed in September 2014, allowing Desano to manufacture tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), as well as elvitegravir (EVG) and the Quad.

In May 2014, the MPP  and Bristol-Myers Squibb signed a sublicensing agreement with the active pharmaceutical ingredient manufacturer Desano allowing it to manufacture atazanavir (ATV).

top

Emcure

Sub-licences covering: lopinavir/ritonavir (LPV/r), daclatasvir (DCV), dolutegravir (DTG), tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], atazanavir (ATV)

The MPP, Emcure and AbbVie signed a sub-licensing agreement, in June 2016, covering lopinavir/ritonavir (LPV/r) for Africa.

In December 2015,  Bristol-Myers Squibb, the MPP and Emcure signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In October 2014, the MPP, Emcure and ViiV Healthcare signed a sub-licensing agreement allowing Emcure to manufacture dolutegravir (DTG) for adults and paediatrics use. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

In September 2014, Emcure, the MPP and Gilead Sciences signed a new sub-licensing agreement, which replaces the previous one signed in January 2012, allowing Emcure to manufacture the novel investigational medicines tenofovir alafenamide (TAF), as well as emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.  The agreement was amended and restated in March 2016.

In July 2014, the MPP and Bristol-Myers Squibb signed a new sublicensing and technology transfer agreement with Emcure allowing it to manufacture atazanavir (ATV).

top

Hetero Labs

Sub-licences covering: atazanavir (ATV), raltegravir paediatrics (RAL), daclatasvir (DCV), lopinavir/ritonavir (LPV/r), tenofovir alafenamide (TAF), dolutegravir (DTG), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In April 2016, MPP, Bristol-Myers Squibb and Hetero Labs signed a new sublicensing agreement allowing Hetero Labs to produce the HIV medicine atazanavir (ATV).

MPP, MSD and Hetero Labs signed a sub-licensing agreement in December 2015, allowing Hetero to manufacture raltegravir (RAL) for paediatric use.

In December 2015,  Bristol-Myers Squibb, the MPP and Hetero Labs signed a sub-licensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In May 2015, the MPP, AbbVie and Hetero Labs signed a sub-licensing agreement, allowing Hetero to manufacture paediatric formulations of  lopinavir and ritonavir (LPV/r) for paediatric use.

In September 2014, Hetero Labs, the MPP and Gilead Sciences signed a sub-licensing agreement, replacing the previous one signed in July 2012,  allowing Hetero Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF), as well emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.  The agreement was amended and restated in September 2015.

In August 2014, Hetero Labs, the MPP and ViiV Healthcare signed a sub-licensing agreement allowing Hetero to manufacture a generic version of dolutegravir (DTG) for both paediatrics and adults use.

top

Huahai Pharmaceutical

Sub-licences covering: tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI).

In May 2015, Huahai Pharmaceutical, the MPP and Gilead Sciences signed a sub-licensing agreement allowing Huahai to manufacture and sell generic versions of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI). In September 2015, Gilead and the MPP clarified section 2.5b(ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

top

Laurus Labs

Sub-licences covering: daclatasvir (DCV), tenofovir alafenamide (TAF), dolutegravir (DTG), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

MPP, Bristol-Myers Squibb and Laurus Labs entered into a sub-licensing agreement in April 2016 allowing Laurus to produce daclatasvir (DCV). 

In September 2014, Laurus Labs, the MPP and Gilead Sciences signed a new sub-licensing agreement, replacing the previous one signed in September 2012, allowing Laurus Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF), as well as tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad. In September 2015, Gilead and the MPP clarified section 2.5b(ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In July 2014, the MPP and ViiV Healthcare signed a sub-licensing agreement with Laurus Labs allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

top

Lupin

Sub-licences covering: raltegravir (RAL) paediatrics, tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), Quad, dolutegravir (DTG)

The MPP, MSD and Lupin signed a sub-licensing agreement in April 2016 allowing Luping to develop and manufacture raltegravir (RAL) for paediatric use. 

In June 2015, the MPP, Lupin and Gilead Sciences signed a sub-licensing agreement allowing Lupin to produce a generic version of tenofovir alafenamide (TAF) as well as of emtricitabine (FTC), cobicistat (COBI) and the Quad.  In September 2015, Gilead and the MPP clarified section 2.5b(ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In June 2015, the MPP announced a sub-licensing agreement with Lupin allowing it to manufacture dolutegravir (DTG) for both paediatrics and adults use.

Micro Labs

Sub-licence covering: tenofovir alafenamide (TAF), emtricitabine (FTC), Quad, dolutegravir (DTG)

In September 2015, the MPP, Micro Labs and Gilead Sciences signed a sub-licensing agreement allowing Micro Labs to produce a generic version of tenofovir alafenamide (TAF) as well as of emtricitabine (FTC) and the Quad.  In September 2015, Gilead and the MPP clarified section 2.5b (ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In July 2014, the MPP and ViiV Healthcare signed a sub-licensing agreement with Micro Labs allowing it to manufacture dolutegravir (DTG) for both adult and paediatric treatment. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

top

Mylan

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Mylan allowing it to manufacture dolutegravir (DTG) for both adult and paediatric use.

top

 

Natco Pharma Limited

Sub-licences covering: daclatasvir (DCV)

In December 2015,  Bristol-Myers Squibb, the MPP and Natco signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

top

Strides Arcolab

Sub-licences covering: dolutegravir (DTG) paediatrics and adults. 

In June 2015, the MPP announced a sub-licensing agreement with Strides Arcolab allowing it to manufacture dolutegravir (DTG) for both paediatrics and adults use.

top

Zydus Cadila

Sub-licence covering:  daclatasvir (DCV)

In April 2016, the MPP, Bristol-Myers Squibb and Zydus Cadila signed a sub-licensing agreement allowing it to manufacture daclatasvir (DCV). 

top

This page is also available in: French, Spanish